APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Abstract Background Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer’s Disease (AD). However, i...

全面介紹

書目詳細資料

Principais autores:	Kristine M. Tran, Nellie E. Kwang, Claire A. Butler, Angela Gomez-Arboledas, Shimako Kawauchi, Cassandra Mar, Donna Chao, Rocio A. Barahona, Celia Da Cunha, Kate I. Tsourmas, Zechuan Shi, Shuling Wang, Sherilyn Collins, Amber Walker, Kai-Xuan Shi, Joshua A. Alcantara, Jonathan Neumann, Duc M. Duong, Nicholas T. Seyfried, Andrea J. Tenner, Frank M. LaFerla, Lindsay A. Hohsfield, Vivek Swarup, Grant R. MacGregor, Kim N. Green
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-01-01
叢編:	Molecular Neurodegeneration
主題:	APOE Christchurch PS19 5xFAD Microglia DAM Amyloid
在線閱讀:	https://doi.org/10.1186/s13024-024-00793-x
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!